Pure Global
NCT06375525

Clinical Trial: The Efficacy of Janssen's Icon Application (App) in Improving Adherence to Treatment With Stimulant Medications in Children With Attention Deficit/Hyperactivity Disorder

Prof. Doron Gothelf MD·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Children Aged 6-18 Years With the Diagnosis of ADHD
Drug/Device/Intervention
Janssen's icon Application (App)
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Prof. Doron Gothelf MD
Funder
Sheba Medical Center
Location
Ramat-Gan, Israel
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2015
End date
Aug 01, 2017
Enrollment
39 participants
Primary outcome

Attention Module of the Kiddie-SADS questionniare

Summary

The overarching aim of the study is to assess the efficacy of Janssen's icon Application
 (App), a digital tool designed to improve adherence to medication treatment in children with
 ADHD.
 
 Our specific hypotheses are:
 
 1. In children receiving medication for ADHD those provided with the App tool will be more
 adherent to treatment than children treated as usual (i.e., not provided with the App
 tool).
 
 2. Adherent patients will show greater improvement of ADHD symptoms and related
 dysfunction.

ICD-10 classifications
Special screening examination for certain developmental disorders in childhoodDevelopmental disorder of scholastic skills, unspecifiedUnspecified behavioural and emotional disorders with onset usually occurring in childhood and adolescenceOther specified behavioural and emotional disorders with onset usually occurring in childhood and adolescenceBehavioural and emotional disorders with onset usually occurring in childhood and adolescence
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06375525
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06375525 through Pure Global AI's free database. This phase not specified trial is sponsored by Prof. Doron Gothelf MD and is currently Completed. The study focuses on Children Aged 6-18 Years With the Diagnosis of ADHD. Target enrollment is 39 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.